Myocardial Injury in Remifentanil-based Versus Sevoflurane-sufentanil Balanced Regimens in OPCAB Surgery
NCT ID: NCT02499445
Last Updated: 2015-07-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
120 participants
INTERVENTIONAL
2007-11-30
2014-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Volatile Versus Propofol Anesthesia in OPCAB
NCT02222142
Anesthesia and Lymphocytes Apoptosis
NCT01461551
Desflurane Versus Propofol Anesthesia for Off-Pump CABG
NCT00528515
Effect of Remimazolam and Propofol on Hemodynamic Stability During Anesthesia Induction in OPCAB Patients
NCT05423951
Remifentanil Anesthesia and Postoperative BIS in Cardiac Surgery
NCT02400879
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients undergoing off-pump coronary artery bypass (OPCAB) surgery are randomly allocated to get remifentanil (0.75 mcg/kg/min) and propofol (TCI effect-site concentration 0.8-1.5 mcg/ml) (Group -RP), remifentanil (0.75 mcg/kg/min) and sevoflurane (end-tidal 0.8 vol%) (Group-RS), or sevoflurane (end-tidal 1.2-2.8 vol%)-sufentanil (TCI effect site concentration0.35-0.75 ng/ml) (Group-SS).
Intergroup difference in the level of Troponin I (c-TnI) and creatine kinase-MB is determined before surgery (control), during vascular graft harvesting (harvesting), after completing graft construction (postgrafting), 1 day after surgery (postoperative).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Remifentanil and propofol
remifentanil (0.75 mcg/kg/min) propofol (TCI effect-site concentration 0.8-1.5 mcg/ml)
Remifentanil
administering remifentanil for anesthesia maintenance
propofol
administering propofol for anesthesia maintenance
remifentanil and sevoflurane 1
remifentanil (0.75 mcg/kg/min) sevoflurane (end-tidal 0.8 vol%)
Remifentanil
administering remifentanil for anesthesia maintenance
sevoflurane 1
administering sevoflurane 1 for anesthesia maintenance
sevoflurane 2 and sufentanil
sevoflurane (end-tidal 1.2-2.8 vol%)-sufentanil (TCI effect site concentration 0.35-0.75 ng/ml)
sevoflurane 2
administering sevoflurane 2 for anesthesia maintenance
sufentanil
administering sufentanil for anesthesia maintenance
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Remifentanil
administering remifentanil for anesthesia maintenance
sevoflurane 1
administering sevoflurane 1 for anesthesia maintenance
sevoflurane 2
administering sevoflurane 2 for anesthesia maintenance
propofol
administering propofol for anesthesia maintenance
sufentanil
administering sufentanil for anesthesia maintenance
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patient signed written informed consent
Exclusion Criteria
* patient with renal replacement therapy
* patient wants to withdraw the participation to the study
19 Years
72 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Konkuk University Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tae-Yop Kim, MD PhD
Professor of Anesthesiology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Konkuk University Medical Center
Seoul, Seoul, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KUH1160004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.